SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SNY Analysis & Videos »
SNY: Bull or Bear?
Access Pharma CEO Interview: Updates and Outlook
SNY
|
|
|
+9.79%
in
73 days
<> Corporate Profile has posted a <font> video interview on YouTube </font> with the President and CEO of Access Pharma (ACCP.ob), Jeffrey B. Davis, which summarizes the compelling investment opportunity represented by his Company. Mr. Davis provides an overview of Access Pharma, explaining that it is not a development-stage company because MuGard has already received marketing clearance by the FDA in the U.S. along with similar approvals worldwide and is in the early stages of its global commercial launch. Furthermore, the Company expects multiple catalysts before year-end which have t...
|
FDA Calendar Updates: POZN, AZN, SNY, CEPH, APPY, CYTR
SNY
|
|
|
+17.61%
in
60 days
(closed on 08/29/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
Access Pharma (OTC:ACCP): Low Valuation, Big Potential
SNY
|
|
|
+0.24%
in
55 days
(closed on 06/30/09)
With shares of Cell Therapeutics (NASDAQ:CTIC) staging the most astonishing comeback I have ever witnessed while rising from 8 cents at the time of <font> my original article in early February </font> to as high as $1.85 during intraday trading today and closing at $1.27 – I went in search of another out-of-favor name in the cancer biotech space. <> Access Pharma (OTC:ACCP) is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to an FDA approved treatment for a side effect of some cancer treatmen...
|
Unilife: Making Syringes Safer, Relocating to U.S.
SNY
|
|
|
+5.63%
in
36 days
(closed on 05/06/09)
For the first time since its public listing in 2002, Unilife Medical Solutions (Australia: UNI.AX) (U.S. ADR: UNIFF.PK) posted a net profit which came in at $11M for the six-month period ending 12/31/08. Unilife posted a 43% increase in revenue to $2.7M, compared to the year-ago period and net income was driven by $23.4M in other income (largely accounted for by a major licensing deal for the Company's pre-filled syringe). The Company ended the year with $10.9M in cash/equivalents and total liabilities of $7.4M ($3.2M current, $4.2M long-term). <> <>http://biomedreport...
|
Updated Clinical Trial and FDA Decision Calendars
SNY
|
|
|
+1.06%
in
11 days
(closed on 03/31/09)
Below is a summary of updates to the BioMedReports.com database of 241 entries included in the FDA and Clinical Trial Calendars. <> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through 3/20/09. The FDA Calendar includes the following information: company name, ticker, decision date, and descrip...
|
Updated Clinical Trial and FDA Decision Calendars
SNY
|
|
|
+0.62%
in
3 days
(closed on 03/20/09)
<> <> Updated Clinical Trial and FDA Calendars
Below is a summary of updates to the www.BioMedReports.co <wbr> </wbr> m database of 243 entries included in the FDA and Clinical Trial Calendars.
http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through today. The FDA Calend...
|
Eli Lilly Sinks After Hours on Effient Delay
SNY
|
|
|
-19.05%
in
13 days
(closed on 10/11/08)
<> 
Eli Lilly (LLY) and Daiichi Sankyo (Tokyo: 4568) announced on Friday evening that the FDA had not completed its regulatory review for its blood thinner drug, which would go by the brand name of Effient (prasugrel). The FDA previously delayed its decision by three months earlier this summer, but in this case no new deadline was set by the agency. Shares of Eli Lilly slid by about 4% after hours on less than 100,000 shares traded, closing near its 52-week low at $45.01 per share on Friday evening. However, the current sli...
|
Bullish on SNY ...
SNY
|
|
|
+15.19%
in
429 days
Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines. The company�s products include Plavix, an anti-platelet agent for various atherothrombotic conditions; Lovenox, a low molecular weight heparin indicated for prophylaxis and treatment of deep vein thrombosis, and for unstable angina and myocardial infarction; Aprovel and Tritace for hypertension treatm...
|
Sanofi Warrants Cheaper Valuation
SNY
+13.78%
in
502 days
While valuation on the combined company is reasonable, we would like to see more visibility on some of the patent issues before we recommend buying the shares.
|
Good entry point for core stock for any portfolio
SNY
|
|
|
+16.90%
in
508 days
Technical Analysis
RSI < 30 and turning. MACD Histogram rising and MACD (7,14,5) about to cross. ADX -DI above 40 for around 3 weeks and now turning.
Thus short-term it seems a good entry point.
Semi-Fundamentals
Great diversification of revenues both by product and regions. Making quick progress into BRIC economies and other promising countries. Strong balance sheet means it can grow either by pipeline investment or acquisition. World population getting older will need more health care.
Warren Buffett and Martin Whitman both value gurus have ope...
|
Sanofi-Aventis: Play This Low-Risk Combo Along with Buffett
SNY
+15.83%
in
509 days
Sanofi–Aventis (SNY) is the 4th
largest drug company in the world and a big holding of Berkshire Hathaway (BRK.A) (BRK.B).
They've earned an 'A+' financial strength rating and an 85th
percentile 'stock price stability' grade from Value Line.
 2008 sales, earnings, cash flow and
dividend payout are all expected to hit all-time highs. Despite that, the ADRs
hit a new four-year low yesterday and now trade at $32.62/ADR.
|
SNY is a buy
SNY
|
|
|
-6.28%
in
871 days
If SNY's cash flow just continues "as is" this company is worth almost twice the current price of about $40.
Hammered by the Accomplia news but is it really bad enough news to keep this company from continuing its current cash flow? No, SNY will be putting all that cash flow to work and growing.
The current price is about 10% cheaper than where Buffett last bought in (but before the Accomplia news)
What's the downside? I can't think there is much room to go down. if there is, I'm buying more.
|
People Bullish on SNY
People Bearish on SNY
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Confidence Restored?
- CONFIDENCE RESTORED?
Have we all of the sudden seen a dramatic improvement in confidence? The action over the last 2 days (the best 2 day gain since 1...
|
More Resources
|
About SanofiAventis
- Answers.com
